Cbdmd Inc Financials
This page shows Cbdmd Inc (YCBD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Loss reduction is being driven by a leaner cost structure, while flat sales and persistent cash burn show operations remain fragile.
Between FY2024 and FY2025, net loss narrowed from-$3.7M to-$2.0M , but operating cash flow deteriorated from-$353K to-$1.5M . With revenue essentially unchanged near$19M and inventory rising from$2.5M to$2.9M , the improvement in reported earnings looks more like expense discipline than a business already converting sales into cash.
Gross margin stayed near
The balance sheet became much less strained in FY2025, with the current ratio rising to 2.1x from 0.7x after liabilities were cut. But cash still eased to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cbdmd Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cbdmd Inc scores -21.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.3M) relative to total liabilities ($3.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cbdmd Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cbdmd Inc generates $0.71 in operating cash flow (-$1.5M OCF vs -$2.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cbdmd Inc earns $-63.0 in operating income for every $1 of interest expense (-$2.2M vs $34K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cbdmd Inc generated $19.2M in revenue in fiscal year 2025. This represents a decrease of 1.5% from the prior year.
Cbdmd Inc's EBITDA was -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.1% from the prior year.
Cbdmd Inc reported -$2.0M in net income in fiscal year 2025. This represents an increase of 44.8% from the prior year.
Cash & Balance Sheet
Cbdmd Inc generated -$1.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 201.5% from the prior year.
Cbdmd Inc held $2.3M in cash against $0 in long-term debt as of fiscal year 2025.
Cbdmd Inc had 9M shares outstanding in fiscal year 2025.
Margins & Returns
Cbdmd Inc's gross margin was 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.8 percentage points from the prior year.
Cbdmd Inc's operating margin was -11.3% in fiscal year 2025, reflecting core business profitability. This is up 5.8 percentage points from the prior year.
Cbdmd Inc's net profit margin was -10.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.4 percentage points from the prior year.
Cbdmd Inc's ROE was -28.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 160.2 percentage points from the prior year.
Capital Allocation
Cbdmd Inc invested $184K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 3.1% from the prior year.
YCBD Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.6M+12.4% | $5.0M+6.3% | $4.7M+2.5% | $4.6M-3.0% | $4.7M-7.1% | $5.1M+12.2% | $4.6M-11.9% | $5.2M |
| Cost of Revenue | $2.4M+18.2% | $2.0M+3.7% | $1.9M+9.5% | $1.8M-0.8% | $1.8M+4.5% | $1.7M-18.5% | $2.1M+18.8% | $1.8M |
| Gross Profit | $3.3M+8.5% | $3.0M+8.1% | $2.8M-1.9% | $2.8M-4.3% | $3.0M-13.0% | $3.4M+38.6% | $2.5M-27.9% | $3.4M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$801K-179.7% | -$286K+58.3% | -$686K+24.2% | -$905K-86.2% | -$486K-463.1% | -$86K+72.7% | -$317K+17.1% | -$382K |
| Interest Expense | $3K-11.1% | $3K-46.0% | $6K-37.9% | $9K+23.2% | $8K-33.0% | $11K+456.0% | $2K+116.1% | -$13K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$798K-181.8% | -$283K+58.4% | -$680K+24.0% | -$895K-86.2% | -$481K-3284.9% | $15K+109.9% | -$153K-133.2% | $460K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $-0.15 |
YCBD Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $12.3M+4.0% | $11.8M+13.1% | $10.4M+5.3% | $9.9M-9.5% | $10.9M-5.2% | $11.5M+9.1% | $10.6M-23.6% | $13.8M |
| Current Assets | $8.4M+2.7% | $8.2M+24.6% | $6.6M+17.1% | $5.6M-9.6% | $6.2M-2.6% | $6.4M-0.4% | $6.4M-12.3% | $7.3M |
| Cash & Equivalents | $2.6M-22.1% | $3.4M+49.8% | $2.3M+113.4% | $1.1M-40.0% | $1.8M-10.4% | $2.0M-19.7% | $2.5M+2.4% | $2.4M |
| Inventory | $3.7M+16.2% | $3.1M+6.7% | $2.9M-7.3% | $3.2M+10.2% | $2.9M+16.6% | $2.5M-2.0% | $2.5M-21.8% | $3.2M |
| Accounts Receivable | $821K+10.2% | $745K-5.3% | $786K+5.4% | $746K+7.4% | $695K+10.1% | $631K+1.5% | $622K-32.1% | $916K |
| Goodwill | $190K | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.0M+7.0% | $2.8M-13.1% | $3.2M-15.6% | $3.8M-63.2% | $10.3M+5.2% | $9.8M+13.3% | $8.6M-20.3% | $10.8M |
| Current Liabilities | $3.0M+7.0% | $2.8M-13.1% | $3.2M-10.9% | $3.6M-63.7% | $9.9M+7.7% | $9.2M+6.4% | $8.6M+9.7% | $7.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.3M+3.1% | $9.0M+24.7% | $7.2M+18.3% | $6.1M+817.8% | $666K-62.6% | $1.8M-9.3% | $2.0M-35.2% | $3.0M |
| Retained Earnings | -$180.6M-0.5% | -$179.8M-0.2% | -$179.4M-0.2% | -$179.1M+3.0% | -$184.5M-0.8% | -$183.1M-0.5% | -$182.1M-0.6% | -$180.9M |
YCBD Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$723K+11.1% | -$812K-237.5% | -$241K+65.8% | -$704K-271.7% | -$189K+40.4% | -$318K-290.0% | $167K-42.2% | $290K |
| Capital Expenditures | $6K-96.5% | $165K+5777.4% | $3K+90.1% | $1K-90.5% | $16K-90.6% | $164K+1543.9% | $10K | $0 |
| Free Cash Flow | -$728K+25.5% | -$977K-301.3% | -$244K+65.5% | -$706K-244.3% | -$205K+57.5% | -$482K-406.5% | $157K-45.7% | $290K |
| Investing Cash Flow | $51K+130.8% | -$165K-5777.4% | -$3K-90.1% | -$1K+90.5% | -$16K+90.6% | -$164K-49.4% | -$110K | $0 |
| Financing Cash Flow | -$78K-103.7% | $2.1M+45.6% | $1.4M | $0 | $0 | $0-100.0% | $1 | $0 |
| Dividends Paid | $15K | N/A | N/A | N/A | $1.0M-0.6% | $1.0M | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
YCBD Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.8%-2.1pp | 59.8%+1.0pp | 58.8%-2.6pp | 61.5%-0.9pp | 62.3%-4.2pp | 66.5%+12.7pp | 53.8%-11.9pp | 65.8% |
| Operating Margin | -14.2%-8.5pp | -5.7%+8.8pp | -14.5%+5.1pp | -19.6%-9.4pp | -10.2%-8.5pp | -1.7%+5.3pp | -7.0%+0.4pp | -7.4% |
| Net Margin | -14.1%-8.5pp | -5.6%+8.8pp | -14.4%+5.0pp | -19.4%-9.3pp | -10.1%-10.4pp | 0.3%+3.7pp | -3.4%-12.2pp | 8.9% |
| Return on Equity | -8.6%-5.5pp | -3.1%+6.3pp | -9.4%+5.2pp | -14.6%+57.6pp | -72.2%-73.1pp | 0.9%+8.6pp | -7.8%-23.0pp | 15.2% |
| Return on Assets | -6.5%-4.1pp | -2.4%+4.1pp | -6.5%+2.5pp | -9.0%-4.7pp | -4.4%-4.5pp | 0.1%+1.6pp | -1.4%-4.8pp | 3.3% |
| Current Ratio | 2.82-0.1 | 2.94+0.9 | 2.05+0.5 | 1.56+0.9 | 0.63-0.1 | 0.69-0.0 | 0.74-0.2 | 0.93 |
| Debt-to-Equity | 0.32+0.0 | 0.31-0.1 | 0.44-0.2 | 0.62-14.8 | 15.43+9.9 | 5.48+1.1 | 4.39+0.8 | 3.57 |
| FCF Margin | -12.9%+6.6pp | -19.5%-14.3pp | -5.2%+10.2pp | -15.3%-11.0pp | -4.3%+5.1pp | -9.4%-12.9pp | 3.5%-2.1pp | 5.6% |
Similar Companies
Frequently Asked Questions
What is Cbdmd Inc's annual revenue?
Cbdmd Inc (YCBD) reported $19.2M in total revenue for fiscal year 2025. This represents a -1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cbdmd Inc's revenue growing?
Cbdmd Inc (YCBD) revenue declined by 1.5% year-over-year, from $19.5M to $19.2M in fiscal year 2025.
Is Cbdmd Inc profitable?
No, Cbdmd Inc (YCBD) reported a net income of -$2.0M in fiscal year 2025, with a net profit margin of -10.6%.
What is Cbdmd Inc's EBITDA?
Cbdmd Inc (YCBD) had EBITDA of -$1.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cbdmd Inc's gross margin?
Cbdmd Inc (YCBD) had a gross margin of 62.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cbdmd Inc's operating margin?
Cbdmd Inc (YCBD) had an operating margin of -11.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cbdmd Inc's net profit margin?
Cbdmd Inc (YCBD) had a net profit margin of -10.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cbdmd Inc's return on equity (ROE)?
Cbdmd Inc (YCBD) has a return on equity of -28.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cbdmd Inc's free cash flow?
Cbdmd Inc (YCBD) generated -$1.6M in free cash flow during fiscal year 2025. This represents a -201.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cbdmd Inc's operating cash flow?
Cbdmd Inc (YCBD) generated -$1.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cbdmd Inc's total assets?
Cbdmd Inc (YCBD) had $10.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cbdmd Inc's capital expenditures?
Cbdmd Inc (YCBD) invested $184K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Cbdmd Inc's current ratio?
Cbdmd Inc (YCBD) had a current ratio of 2.05 as of fiscal year 2025, which is generally considered healthy.
What is Cbdmd Inc's debt-to-equity ratio?
Cbdmd Inc (YCBD) had a debt-to-equity ratio of 0.44 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cbdmd Inc's return on assets (ROA)?
Cbdmd Inc (YCBD) had a return on assets of -19.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cbdmd Inc's cash runway?
Based on fiscal year 2025 data, Cbdmd Inc (YCBD) had $2.3M in cash against an annual operating cash burn of $1.5M. This gives an estimated cash runway of approximately 19 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cbdmd Inc's Altman Z-Score?
Cbdmd Inc (YCBD) has an Altman Z-Score of -21.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cbdmd Inc's Piotroski F-Score?
Cbdmd Inc (YCBD) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cbdmd Inc's earnings high quality?
Cbdmd Inc (YCBD) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cbdmd Inc cover its interest payments?
Cbdmd Inc (YCBD) has an interest coverage ratio of -63.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cbdmd Inc?
Cbdmd Inc (YCBD) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.